肝纤维化和肝癌是肝纤维化的原因之一
Aina Anton1, Scott Laurence Friedman2, Bruno Cogliati3,2
1Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas, Madrid, Spain.
肝纤维化,不仅仅是肝硬化,可以启动肝癌 (肝细胞癌,HCC). 纤维化重塑肝脏的微环境,促进炎症和免疫抑制,甚至在肝硬化之前推动癌症的发展.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 肝细胞癌 (HCC) 通常发生在纤维化的肝脏中,肝硬化是已知的危险因素.
- 新兴证据表明,肝纤维化,特别是与代谢功能障碍相关的脂肪性肝病 (MASLD) 相关的肝纤维化,可以独立于肝硬化驱动肝癌发生.
- 肝星细胞 (HSC) 和瘤微环境在这个过程中起着至关重要的作用.
研究的目的:
- 审查将肝纤维化与肝细胞癌 (HCC) 发病联系起来的机制性见解.
- 探索肝星细胞 (HSC) 生物学和瘤免疫学在纤维化驱动的肝癌发生中的作用.
- 要突出纤维化如何创建一个前恶性利基促进HCC发展.
主要方法:
- 本综述综合了有关肝星细胞 (HSC) 生物学和瘤免疫学的当前文献.
- 讨论了对细胞外矩阵 (ECM) 改造,免疫监测重编程和代谢交叉通话的机制性见解.
- 研究了衰老和细胞衰老在放大前瘤源信号传递中的作用.
主要成果:
- 纤维性肝脏重塑增加了ECM的刚性,破坏了肝脏结构,并促进了异常血管生成.
- 肝星细胞 (HSC) 重新编程免疫微环境,导致免疫细胞排除和免疫抑制.
- 衰老和衰老加剧了纤维化相关的炎症和免疫功能障碍,加强了干性和治疗抵抗力.
结论:
- 纤维化作为HCC的关键煽动者,通过为恶性转变创造一个允许的微环境.
- 纤维素信号传递,免疫失调和代谢因素之间的相互作用驱动HCC的发展.
- 了解这些机制揭示了HCC预防和治疗的潜在治疗点.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
08:40A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
Published on: August 7, 2020
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
